The low sensitivity of tests developed so far encourages the use of a combination of several markers in the assay, suggesting that such a combination could ultimately constitute a biomarker panel for prostate cancer detection, as proposed by Yoneyama et al. To identify clinically significant prostate cancer (CSPC), they evaluated the amount of LacdiNAc-glycosylated prostate-specific antigen (LDN-PSA) and LDN-PSA normalized by prostate volume (LDN-PSAD). This evidence concerns the gene KLK3 and Familial prostate cancer.